Immunotherapy Administration

{
  "compose" : {
    "exclude" : [ ],
    "include" : [ {
      "valueSet" : [ "http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.177" ]
    }, {
      "valueSet" : [ "http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.175" ]
    }, {
      "valueSet" : [ "http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.174" ]
    } ]
  },
  "date" : "2022-03-03T18:46:01-05:00",
  "meta" : {
    "versionId" : "12",
    "lastUpdated" : "2023-12-21T17:43:03.000-05:00",
    "profile" : [ "http://hl7.org/fhir/StructureDefinition/shareablevalueset", "http://hl7.org/fhir/us/cqfmeasures/StructureDefinition/computable-valueset-cqfm", "http://hl7.org/fhir/us/cqfmeasures/StructureDefinition/publishable-valueset-cqfm" ]
  },
  "publisher" : "American Society of Clinical Oncology Steward",
  "jurisdiction" : [ {
    "coding" : [ {
      "system" : "urn:iso:std:iso:3166",
      "code" : "US"
    } ]
  } ],
  "purpose" : "(Clinical Focus: The purpose of this value set is to represent concepts for the procedure of immunotherapy administration.),(Data Element Scope: This value set may use a model element related to Procedure.),(Inclusion Criteria: Includes concepts that represent a procedure for immunotherapy administration.),(Exclusion Criteria: No exclusions.)",
  "name" : "ImmunotherapyAdministration",
  "experimental" : false,
  "resourceType" : "ValueSet",
  "expansion" : {
    "contains" : [ {
      "system" : "http://snomed.info/sct",
      "code" : "180223008",
      "display" : "Intravenous immunotherapy (procedure)",
      "version" : "http://snomed.info/sct/731000124108/version/20230901"
    }, {
      "system" : "http://snomed.info/sct",
      "code" : "180244008",
      "display" : "Intramuscular immunotherapy (procedure)",
      "version" : "http://snomed.info/sct/731000124108/version/20230901"
    }, {
      "system" : "http://snomed.info/sct",
      "code" : "180256009",
      "display" : "Subcutaneous immunotherapy (procedure)",
      "version" : "http://snomed.info/sct/731000124108/version/20230901"
    }, {
      "system" : "http://snomed.info/sct",
      "code" : "589631000119102",
      "display" : "Intravenous radioimmunotherapy using monoclonal antibodies (procedure)",
      "version" : "http://snomed.info/sct/731000124108/version/20230901"
    }, {
      "system" : "http://snomed.info/sct",
      "code" : "60827006",
      "display" : "Lymphokine activated killer cell therapy (procedure)",
      "version" : "http://snomed.info/sct/731000124108/version/20230901"
    }, {
      "system" : "http://snomed.info/sct",
      "code" : "64644003",
      "display" : "Immunotherapy for cancer (procedure)",
      "version" : "http://snomed.info/sct/731000124108/version/20230901"
    }, {
      "system" : "http://snomed.info/sct",
      "code" : "72255009",
      "display" : "Interleukin-2 therapy (procedure)",
      "version" : "http://snomed.info/sct/731000124108/version/20230901"
    }, {
      "system" : "http://snomed.info/sct",
      "code" : "76334006",
      "display" : "Immunotherapy (procedure)",
      "version" : "http://snomed.info/sct/731000124108/version/20230901"
    }, {
      "system" : "http://snomed.info/sct",
      "code" : "84501003",
      "display" : "Cytokine therapy (procedure)",
      "version" : "http://snomed.info/sct/731000124108/version/20230901"
    }, {
      "system" : "http://snomed.info/sct",
      "code" : "870387009",
      "display" : "Immune checkpoint inhibitor therapy (procedure)",
      "version" : "http://snomed.info/sct/731000124108/version/20230901"
    }, {
      "system" : "http://www.ama-assn.org/go/cpt",
      "code" : "96365",
      "display" : "Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour",
      "version" : "2024"
    }, {
      "system" : "http://www.ama-assn.org/go/cpt",
      "code" : "96366",
      "display" : "Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); each additional hour (List separately in addition to code for primary procedure)",
      "version" : "2024"
    }, {
      "system" : "http://www.ama-assn.org/go/cpt",
      "code" : "96372",
      "display" : "Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular",
      "version" : "2024"
    }, {
      "system" : "http://www.ama-assn.org/go/cpt",
      "code" : "96374",
      "display" : "Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); intravenous push, single or initial substance/drug",
      "version" : "2024"
    }, {
      "system" : "http://www.ama-assn.org/go/cpt",
      "code" : "96401",
      "display" : "Chemotherapy administration, subcutaneous or intramuscular; non-hormonal anti-neoplastic",
      "version" : "2024"
    }, {
      "system" : "http://www.ama-assn.org/go/cpt",
      "code" : "96409",
      "display" : "Chemotherapy administration; intravenous, push technique, single or initial substance/drug",
      "version" : "2024"
    }, {
      "system" : "http://www.ama-assn.org/go/cpt",
      "code" : "96413",
      "display" : "Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug",
      "version" : "2024"
    }, {
      "system" : "http://www.ama-assn.org/go/cpt",
      "code" : "96415",
      "display" : "Chemotherapy administration, intravenous infusion technique; each additional hour (List separately in addition to code for primary procedure)",
      "version" : "2024"
    }, {
      "system" : "http://www.ama-assn.org/go/cpt",
      "code" : "96416",
      "display" : "Chemotherapy administration, intravenous infusion technique; initiation of prolonged chemotherapy infusion (more than 8 hours), requiring use of a portable or implantable pump",
      "version" : "2024"
    }, {
      "system" : "http://www.nlm.nih.gov/research/umls/hcpcs",
      "code" : "Q2041",
      "display" : "Axicabtagene ciloleucel, up to 200 million autologous anti-cd19 car positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose",
      "version" : "2024"
    }, {
      "system" : "http://www.nlm.nih.gov/research/umls/hcpcs",
      "code" : "Q2042",
      "display" : "Tisagenlecleucel, up to 600 million car-positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose",
      "version" : "2024"
    } ],
    "total" : 21,
    "identifier" : "urn:uuid:f63aee14-d1ad-4e34-a543-c702c9360c67",
    "timestamp" : "2024-04-23T13:44:11-04:00"
  },
  "title" : "Immunotherapy Administration",
  "extension" : [ {
    "valueString" : "American Society of Clinical Oncology Author",
    "url" : "http://hl7.org/fhir/StructureDefinition/valueset-author"
  }, {
    "valueDate" : "2023-06-23",
    "url" : "http://hl7.org/fhir/StructureDefinition/resource-lastReviewDate"
  }, {
    "valueDate" : "2021-03-20",
    "url" : "http://hl7.org/fhir/StructureDefinition/valueset-effectiveDate"
  }, {
    "url" : "http://health-samurai.io/extensions/source",
    "valueCode" : "db"
  } ],
  "status" : "active",
  "id" : "d7633f61-ba07-4658-b195-7e6fa09ac73d",
  "url" : "http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.5.226",
  "identifier" : [ {
    "system" : "urn:ietf:rfc:3986",
    "value" : "urn:oid:2.16.840.1.113883.3.1444.5.226"
  } ],
  "version" : "20210320"
}